Suppr超能文献

SQ 14,225(一种口服活性血管紧张素I转换酶抑制剂)对大鼠的降压活性。

Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme.

作者信息

Laffan R J, Goldberg M E, High J P, Schaeffer T R, Waugh M H, Rubin B

出版信息

J Pharmacol Exp Ther. 1978 Feb;204(2):281-8.

PMID:202693
Abstract

SQ 14,225 (D-3-mercapto-2-methylpropanoyl-L-proline) markedly lowered the blood pressure of the renin-dependent aortic-ligated and two-kidney Goldblatt hypertensive rat and failed to reduce blood pressure in the one-kidney Goldblatt hypertensive rat. In the two-kidney Goldblatt rat, SQ 14,225 (p.o.) was about 10 times as potent as teprotide, the nonapeptide SQ 20,881 (s.c.). Oral doses of SQ 14,225 moderately reduced the blood pressure of the Wistar-Kyoto spontaneously hypertensive rat but not that of the normotensive Wistar-Kyoto rat. Bilateral nephrectomy abolished the antihypertensive activity of SQ 14,225 in the spontaneously hypertensive rat. SQ 14,225 and SQ 20,881 elicited parallel dose-response curves in the two-kidney renal hypertensive rat. Post-treatment of spontaneously hypertensive rats with either agent failed to augment the antihypertensive effect produced by effective doses of the other agent. The results suggest that SQ 14,225 acts primarily by inhibiting the renin-angiotensin system to reduce elevated blood pressure, especially in presumably renin-dependent models of hypertension.

摘要

SQ 14,225(D-3-巯基-2-甲基丙酰基-L-脯氨酸)可显著降低肾素依赖性主动脉结扎和双肾Goldblatt高血压大鼠的血压,但对单肾Goldblatt高血压大鼠的血压无降低作用。在双肾Goldblatt大鼠中,口服SQ 14,225的效力约为非肽类SQ 20,881皮下注射效力的10倍。口服剂量的SQ 14,225可适度降低Wistar-Kyoto自发性高血压大鼠的血压,但对正常血压的Wistar-Kyoto大鼠无效。双侧肾切除消除了SQ 14,225对自发性高血压大鼠的降压活性。在双肾肾性高血压大鼠中,SQ 14,225和SQ 20,881呈现平行的剂量反应曲线。用任何一种药物对自发性高血压大鼠进行后处理,均不能增强另一种有效剂量药物产生的降压效果。结果表明,SQ 14,225主要通过抑制肾素-血管紧张素系统来降低血压升高,特别是在可能依赖肾素的高血压模型中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验